JPMorgan raised the firm’s price target on Ideaya Biosciences to $51 from $41 and keeps an Overweight rating on the shares. The analyst also added the shares to the firm’s Analyst Focus List. The company was enthusiastic on the potential of darovasertib in the neoadjuvant uveal melanoma setting, with data anticipated mid-2024, the analyst tells investors in a research note. The firm says the known darovasertib data is encouraging, thus de-risking the mid-year update.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IDYA:
- Oppenheimer, Wedbush say buy these biotech stocks for 2024
- Ideaya Biosciences to hold a virtual meeting
- Ideaya Biosciences enters clinical study pact, supply agreement with Gilead
- Ideaya Biosciences price target raised to $41 from $35 at JPMorgan
Questions or Comments about the article? Write to editor@tipranks.com